MicroRNA‑503 suppresses cell proliferation and invasion in osteosarcoma via targeting insulin‑like growth factor 1 receptor Retraction in /10.3892/etm.2021.10845

Wang,Zili; Zheng,Chenhuang; Jiang,Kunqi; He,Jinshen; Cao,Xu; Wu,Song

doi:10.3892/etm.2017.4648

MicroRNA‑503 suppresses cell proliferation and invasion in osteosarcoma via targeting insulin‑like growth factor 1 receptor

Retraction in: /10.3892/etm.2021.10845

Authors:
- Zili Wang
- Chenhuang Zheng
- Kunqi Jiang
- Jinshen He
- Xu Cao
- Song Wu
View Affiliations

Affiliations: Department of Orthopedics, Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China
Published online on: June 22, 2017 https://doi.org/10.3892/etm.2017.4648
Pages: 1547-1553
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRs) are a class of small non‑coding RNAs and have key roles in various cancer types. Recently, miR‑503 has been reported to act as a tumor suppressor in osteosarcoma. However, the detailed mechanism of the regulatory role of miR‑503 in osteosarcoma cell proliferation and invasion has largely remained elusive. The present study found that miR‑503 was significantly downregulated in osteosarcoma tissues compared to that in matched adjacent non‑tumorous tissues. In addition, the expression of miR‑503 in osteosarcoma of T3‑T4 stage was significantly lower when compared with that in T1‑T2 stage samples. miR‑503 was also downregulated in osteosarcoma cell lines (Saos‑2, MG63, U2OS and SW1353), when compared with that in the normal osteoblast cell line hFOB. Overexpression of miR‑503 significantly inhibited the proliferation and invasion of U2OS cells and decreased the protein levels of insulin‑like growth factor 1 receptor (IGF‑1R), which was further identified as a novel target of miR‑503 by a luciferase reporter assay. Moreover, overexpression of IGF‑1R eliminated the suppressive effects of miR‑503 on the proliferation and invasion of U2OS cells, suggesting that miR‑503 inhibits osteosarcoma cell proliferation and invasion by directly targeting IGF‑1R. Furthermore, IGF‑1R was significantly upregulated in osteosarcoma tissues compared with that in adjacent non‑tumor tissues, as well as in osteosarcoma cell lines compared with that in hFOB cells. In addition, the expression levels of IGF‑1R were inversely correlated to the miR‑503 levels in osteosarcoma tissues, suggesting that the increased IGF‑1R expression may be caused by the reduced expression of miR‑503. In conclusion, the present study demonstrated that miR‑503 suppresses cell proliferation and invasion in osteosarcoma via targeting IGF‑1R and thus highlights the importance of miR‑503/IGF‑1R signaling in the malignant progression of osteosarcoma.

View Figures

View References

1	Thompson LD: Osteosarcoma. Ear Nose Throat J. 92:288–290. 2013.PubMed/NCBI
2	Wu X, Zhong D, Gao Q, Zhai W, Ding Z and Wu J: MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether à go-go 1 expression. Int J Med Sci. 10:676–682. 2013. View Article : Google Scholar : PubMed/NCBI
3	Shin VY, Siu JM, Cheuk I, Ng EK and Kwong A: Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer. 112:1751–1759. 2015. View Article : Google Scholar : PubMed/NCBI
4	DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014. View Article : Google Scholar : PubMed/NCBI
5	Munagala R, Aqil F, Vadhanam MV and Gupta RC: MicroRNA ‘signature’ during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention. Cancer Lett. 339:175–184. 2013. View Article : Google Scholar : PubMed/NCBI
6	Negrini M and Calin GA: Breast cancer metastasis: A microRNA story. Breast Cancer Res. 10:2032008. View Article : Google Scholar : PubMed/NCBI
7	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
8	John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS: Human MicroRNA targets. PLoS Biol. 2:e3632004. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
11	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
12	Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, Yoshioka Y, Kobayashi E, Yamada T, Kawai A, Inoue T, et al: MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther. 19:1123–1130. 2011. View Article : Google Scholar : PubMed/NCBI
13	Huang G, Nishimoto K, Zhou Z, Hughes D and Kleinerman ES: miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res. 72:908–916. 2012. View Article : Google Scholar : PubMed/NCBI
14	Jin J, Cai L, Liu ZM and Zhou XS: miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev. 14:3681–3684. 2013. View Article : Google Scholar : PubMed/NCBI
15	Duan Z, Choy E, Harmon D, Liu X, Susa M, Mankin H and Hornicek F: MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther. 10:1337–1345. 2011. View Article : Google Scholar : PubMed/NCBI
16	Bassampour SA, Abdi R, Bahador R, Shakeri M, Torkaman A, Yahaghi E and Taheriazam A: Downregulation of miR-133b/miR-503 acts as efficient prognostic and diagnostic factors in patients with osteosarcoma and these predictor biomarkers are correlated with overall survival. Tumour Biol. Aug 16–2015.(Epub ahead of print). PubMed/NCBI
17	Chong Y, Zhang J, Guo X, Li G, Zhang S, Li C, Jiao Z and Shao M: MicroRNA-503 acts as a tumor suppressor in osteosarcoma by targeting L1CAM. PLoS One. 9:e1145852014. View Article : Google Scholar : PubMed/NCBI
18	Wu B and Bi W: Role of microRNA-503 in the suppression of osteosarcoma cell proliferation and migration via modulation of fibroblast growth factor 2. Mol Med Rep. 12:7433–7438. 2015.PubMed/NCBI
19	Guo X, Zhang J, Pang J, He S, Li G, Chong Y, Li C, Jiao Z, Zhang S and Shao M: MicroRNA-503 represses epithelial-mesenchymal transition and inhibits metastasis of osteosarcoma by targeting c-myb. Tumour Biol. 37:91881–9187. 2016. View Article : Google Scholar
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Chen G, Fang T, Huang Z, Qi Y, Du S, Di T, Lei Z, Zhang X and Yan W: MicroRNA-133a inhibits osteosarcoma cells proliferation and invasion via targeting IGF-1R. Cell Physiol Biochem. 38:598–608. 2016. View Article : Google Scholar : PubMed/NCBI
22	Peng Y, Liu YM, Li LC, Wang LL and Wu XL: microRNA-503 inhibits gastric cancer cell growth and epithelial-to-mesenchymal transition. Oncol Lett. 7:1233–1238. 2014.PubMed/NCBI
23	Liu L, Qu W and Zhong Z: Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC. Int J Clin Exp Pathol. 8:5609–5613. 2015.PubMed/NCBI
24	Xiao F, Zhang W, Chen L, Xie H, Xing C, Yu X, Ding S, Chen K, Guo H, Cheng J, et al: MicroRNA-503 inhibits the G1/S transition by downregulating cyclin D3 and E2F3 in hepatocellular carcinoma. J Transl Med. 11:1952013. View Article : Google Scholar : PubMed/NCBI
25	Chang SW, Yue J, Wang BC and Zhang XL: miR-503 inhibits cell proliferation and induces apoptosis in colorectal cancer cells by targeting E2F3. Int J Clin Exp Pathol. 8:12853–12860. 2015.PubMed/NCBI
26	Ide S, Toiyama Y, Shimura T, Kawamura M, Yasuda H, Saigusa S, Ohi M, Tanaka K, Mohri Y and Kusunoki M: MicroRNA-503 promotes tumor progression and acts as a novel biomarker for prognosis in oesophageal cancer. Anticancer Res. 35:1447–1451. 2015.PubMed/NCBI
27	King H, Aleksic T, Haluska P and Macaulay VM: Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev. 40:1096–1105. 2014. View Article : Google Scholar : PubMed/NCBI
28	Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, Houghton P and Gorlick R: R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer. 55:67–75. 2010.PubMed/NCBI
29	Maniscalco L, Iussich S, Morello E, Martano M, Gattino F, Miretti S, Biolatti B, Accornero P, Martignani E, Sánchez-Céspedes R, et al: Increased expression of insulin-like growth factor-1 receptor is correlated with worse survival in canine appendicular osteosarcoma. Vet J. 205:272–280. 2015. View Article : Google Scholar : PubMed/NCBI
30	Liang J, Li B, Yuan L and Ye Z: Prognostic value of IGF-1R expression in bone and soft tissue sarcomas: A meta-analysis. Onco Targets Ther. 8:1949–1955. 2015.PubMed/NCBI